search
Back to results

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Primary Purpose

Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Plasma ctDNA
FFPE blocks
Sponsored by
Intergroupe Francophone de Cancerologie Thoracique
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Non Small Cell Lung Cancer focused on measuring IFCT, NSCLC, Adjuvant Osimertinib

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Signed Informed consent. Age ≥ 18 years. Pre-surgical disease evaluation including brain MRI/CT-scan and total body PET-FDG CT-scan prior to surgery. Histologically complete anatomical resection (R0) of stage pIB-IIIA (pTNM 8th edition) NSCLC. Presence of a common EGFR mutation (Del19 or L858R). Archival tumour tissue FFPE blocks from surgery available for centrally molecular analyses. Patient eligible to receive osimertinib adjuvant therapy in a 3-year intent to treat decision; patients could receive if necessary adjuvant chemotherapy before starting osimertinib treatment. Patient who is capable, according to the investigator, of complying with the study's requirements and restrictions. Patient followed in the institution on a regular basis (every 3 to 6 months) according to standard recommendations. Estimated life expectancy > 3 years. Woman patients who are of childbearing potential are eligible: They must have a negative pregnancy test before the first dose of osimertinib. They must agree to use effective methods of contraception throughout the course of treatment and should be maintained for 2 months after the end of treatment. Male subjects who are sexually active with a woman of childbearing potential are eligible if an efficacious contraception method should be used during the treatment and during the 4 months following the last dose. Exclusion Criteria: History of cancer, except for the following situations: Patients with history of cancer for more than 3 years are eligible if they have been treated and considered cured. Patients with history of in situ carcinoma of the cervix or non-melanoma skin carcinoma are eligible. Neoadjuvant anti-cancer treatment (osimertinib and/or chemotherapy or other anti-cancer treatment). Incompletely resected NSCLC (R1 or R2). Any medical condition that would, according to the investigator's judgment, prevent the patient's participation in the clinical study. Active infection (e.g. patients receiving treatment for infection) including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), or active uncontrolled hepatitis B infection except for the situations described in APPENDIX I. Screening for chronic conditions is not required.

Sites / Locations

  • Angers - CHU
  • Bayonne - CH
  • Boulogne - Ambroise Paré
  • Lyon - URCOT
  • Caen - CHU
  • Clermont-Ferrand - CHU
  • Colmar - CH
  • Créteil - CHI
  • Dijon - CHU Bocage
  • Grenoble - CHU
  • La Roche-Sur-Yon - CH
  • Le Mans - CHG
  • Lille - CHU
  • Lyon - CRLCC
  • Marseille - APHM
  • Metz - Hôpital Robert Schuman
  • Montpellier - CHU
  • Montpellier - ICM
  • Nice - CHU
  • Orléans - CHR
  • Paris - Bichat
  • Paris - HEGP
  • Paris - Hôpital Cochin
  • Paris - Pitié-Salpêtrière
  • Paris - Tenon
  • Pau - CHG
  • Bordeaux - CHU
  • Poitiers - CHU
  • Annecy - CH
  • Rennes - CHU
  • Rouen - CHU
  • Strasbourg - NHC
  • Suresnes - Foch
  • Toulon - CHI
  • Toulouse - CHU
  • Tours - CHU

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Plasma ctDNA and FFPE blocks

Arm Description

Outcomes

Primary Outcome Measures

Feasibility study
Number of patients included receiving osimertinib after 18 months of enrollment

Secondary Outcome Measures

Incidence, nature, and severity of osimertinib-related adverse events (safety)
Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0).

Full Information

First Posted
August 18, 2023
Last Updated
September 19, 2023
Sponsor
Intergroupe Francophone de Cancerologie Thoracique
search

1. Study Identification

Unique Protocol Identification Number
NCT06053099
Brief Title
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Acronym
ROSIE
Official Title
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
October 2031 (Anticipated)
Study Completion Date
October 2031 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Intergroupe Francophone de Cancerologie Thoracique

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
IFCT-2202 ROSIE study aims to incorporate a broad-panel centralized NGS testing at baseline in all patients with completely resected NSCLC with common EGFR mutation after confirmation of an optimal preoperative extension assessment and with a centralized review of the quality of the surgical excision. Furthermore, the IFCT-2202 ROSIE study also aims to study the molecular events associated with relapse on, or after osimertinib exposure, that should result in the opportunity to accede to optimal treatment in case of metastatic relapse.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
Keywords
IFCT, NSCLC, Adjuvant Osimertinib

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Plasma ctDNA and FFPE blocks
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Plasma ctDNA
Intervention Description
Plasma ctDNA before surgery (optional) Plasma ctDNA post-surgery : 4 to 8 weeks post-surgery, before starting adjuvant chemotherapy (if given) and before starting adjuvant osimertinib (if given) Plasma ctDNA every 6 months Plasma ctDNA at relapse
Intervention Type
Other
Intervention Name(s)
FFPE blocks
Intervention Description
Surgery FFPE blocks FFPE blocks at relapse (optional)
Primary Outcome Measure Information:
Title
Feasibility study
Description
Number of patients included receiving osimertinib after 18 months of enrollment
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Incidence, nature, and severity of osimertinib-related adverse events (safety)
Description
Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0).
Time Frame
About 3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed Informed consent. Age ≥ 18 years. Pre-surgical disease evaluation including brain MRI/CT-scan and total body PET-FDG CT-scan prior to surgery. Histologically complete anatomical resection (R0) of stage pIB-IIIA (pTNM 8th edition) NSCLC. Presence of a common EGFR mutation (Del19 or L858R). Archival tumour tissue FFPE blocks from surgery available for centrally molecular analyses. Patient eligible to receive osimertinib adjuvant therapy in a 3-year intent to treat decision; patients could receive if necessary adjuvant chemotherapy before starting osimertinib treatment. Patient who is capable, according to the investigator, of complying with the study's requirements and restrictions. Patient followed in the institution on a regular basis (every 3 to 6 months) according to standard recommendations. Estimated life expectancy > 3 years. Woman patients who are of childbearing potential are eligible: They must have a negative pregnancy test before the first dose of osimertinib. They must agree to use effective methods of contraception throughout the course of treatment and should be maintained for 2 months after the end of treatment. Male subjects who are sexually active with a woman of childbearing potential are eligible if an efficacious contraception method should be used during the treatment and during the 4 months following the last dose. Exclusion Criteria: History of cancer, except for the following situations: Patients with history of cancer for more than 3 years are eligible if they have been treated and considered cured. Patients with history of in situ carcinoma of the cervix or non-melanoma skin carcinoma are eligible. Neoadjuvant anti-cancer treatment (osimertinib and/or chemotherapy or other anti-cancer treatment). Incompletely resected NSCLC (R1 or R2). Any medical condition that would, according to the investigator's judgment, prevent the patient's participation in the clinical study. Active infection (e.g. patients receiving treatment for infection) including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), or active uncontrolled hepatitis B infection except for the situations described in APPENDIX I. Screening for chronic conditions is not required.
Facility Information:
Facility Name
Angers - CHU
City
Angers
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Youssef OULKHOUIR
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Youssef OULKHOUIR, Dr
Facility Name
Bayonne - CH
City
Bayonne
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie SCHNEIDER
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Sophie SCHNEIDER, Dr
Facility Name
Boulogne - Ambroise Paré
City
Boulogne
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Etienne GIROUX LEPRIEUR
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Etienne GIROUX LEPRIEUR, Pr
Facility Name
Lyon - URCOT
City
Bron
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas PIERRET
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Thomas PIERRET, Dr
Facility Name
Caen - CHU
City
Caen
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeannick MADELAINE
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Jeannick MADELAINE, Dr
Facility Name
Clermont-Ferrand - CHU
City
Clermont-Ferrand
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick MERLE
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Patrick MERLE
Facility Name
Colmar - CH
City
Colmar
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lionel MOREAU
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Lionel MOREAU, Dr
Facility Name
Créteil - CHI
City
Créteil
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabelle MONNET
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Isabelle MONNET, Dr
Facility Name
Dijon - CHU Bocage
City
Dijon
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ayoube ZOUAK
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Ayoube ZOUAK, Dr
Facility Name
Grenoble - CHU
City
Grenoble
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne-Claire TOFFART
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Anne-Claire TOFFART, Pr
Facility Name
La Roche-Sur-Yon - CH
City
La Roche-sur-Yon
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cyril GUIBERT
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Cyril GUIBERT, Dr
Facility Name
Le Mans - CHG
City
Le Mans
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Camille GUGUEN
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Dr Camille GUGUEN, Dr
Facility Name
Lille - CHU
City
Lille
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexis CORTOT
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Alexis CORTOT, Pr
Facility Name
Lyon - CRLCC
City
Lyon
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Virginie AVRILLON
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Virginie AVRILLON, Dr
Facility Name
Marseille - APHM
City
Marseille
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascale TOMASINI
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Pascale TOMASINI, Dr
Facility Name
Metz - Hôpital Robert Schuman
City
Metz
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benoît GODBERT, Dr
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Benoît GODBERT
Facility Name
Montpellier - CHU
City
Montpellier
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benoit ROCH
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Benoit ROCH, Dr
Facility Name
Montpellier - ICM
City
Montpellier
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Quentin THOMAS
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Quentin THOMAS, Dr
Facility Name
Nice - CHU
City
Nice
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan BENZAQUEN
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Jonathan BENZAQUEN, Dr
Facility Name
Orléans - CHR
City
Orléans
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hugues MOREL
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Hugues MOREL, Dr
Facility Name
Paris - Bichat
City
Paris
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gérard ZALCMAN
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Gérard ZALCMAN, Pr
Facility Name
Paris - HEGP
City
Paris
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth FABRE
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Elizabeth FABRE, Dr
Facility Name
Paris - Hôpital Cochin
City
Paris
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie WISLEZ
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Marie WISLEZ, Pr
Facility Name
Paris - Pitié-Salpêtrière
City
Paris
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aurore VOZY
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Aurore VOZY, Dr
Facility Name
Paris - Tenon
City
Paris
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pr Jacques CADRANEL
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Pr Jacques CADRANEL, Pr
Facility Name
Pau - CHG
City
Pau
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aldo RENAULT
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Aldo RENAULT, Dr
Facility Name
Bordeaux - CHU
City
Pessac
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maéva ZYSMAN
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Maéva ZYSMAN, Dr
Facility Name
Poitiers - CHU
City
Poitiers
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clotilde DELDYCKE
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Clotilde DELDYCKE, Dr
Facility Name
Annecy - CH
City
Pringy
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Valérie PAULUS-JACQUEMET
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Valérie PAULUS-JACQUEMET, Dr
Facility Name
Rennes - CHU
City
Rennes
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charles RICORDEL
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Charles RICORDEL, Dr
Facility Name
Rouen - CHU
City
Rouen
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florian GUISIER
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Florian GUISIER, Pr
Facility Name
Strasbourg - NHC
City
Strasbourg
ZIP/Postal Code
63000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Céline MASCAUX, Dr
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Céline MASCAUX, Pr
Facility Name
Suresnes - Foch
City
Suresnes
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra BIZOT
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Alexandra BIZOT, Dr
Facility Name
Toulon - CHI
City
Toulon
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clarisse AUDIGIER-VALETTE
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Clarisse AUDIGIER-VALETTE, Dr
Facility Name
Toulouse - CHU
City
Toulouse
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurence BIGAY-GAME
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Laurence BIGAY-GAME, Dr
Facility Name
Tours - CHU
City
Tours
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Delphine Carmier
Phone
+33 1.56.81.10.45
Email
contact@ifct.fr
First Name & Middle Initial & Last Name & Degree
Delphine Carmier, Dr

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

We'll reach out to this number within 24 hrs